Literature DB >> 6240448

Regression of cardiovascular structural changes by antihypertensive treatment. Functional consequences and time course of reversal as judged from clinical studies.

B Trimarco, J Wikstrand.   

Abstract

Echocardiographic studies have shown a decrease in left ventricular (LV) wall thickness and an improvement in LV function during antihypertensive treatment. A reduction in LV mass parallels the reduction in LV wall thickness during the first year of antihypertensive treatment, but thereafter favorable changes in LV wall thickness, cardiac output, and total peripheral resistance may be recorded in spite of a constant LV mass. The reason for this is that LV mass is defined by LV wall thickness and LV end-diastolic diameter, and that LV mass may stay unchanged if LV wall thickness decreases when LV diameter increases. This pattern of change is to be expected since LV distensibility and, hence, LV end-diastolic diameter may increase when LV wall thickness decreases. The effect of treatment may thus be divided into two main phases--an initial phase with a reduction in LV mass and a reduction in cardiac output and no change in total peripheral resistance--and a second phase with a constant LV mass but an increase in cardiac output to the pretreatment level again and a concomitant decrease in total peripheral resistance. The increase in stroke volume and cardiac output during this second phase of treatment is mainly dependent on an increase in end-diastolic volume, most likely explained by improved LV compliance when LV wall thickness decreases. The concomitant decrease in total peripheral resistance is mainly explained by reversal of structural vascular changes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240448     DOI: 10.1161/01.hyp.6.6_pt_2.iii150

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Left ventricular hypertrophy: unresolved issues.

Authors:  J A Schoenberger
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 2.  Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs.

Authors:  W Motz; B E Strauer
Journal:  Clin Investig       Date:  1992

Review 3.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

4.  Comparison between the effects of urapidil and methyldopa on left ventricular hypertrophy and haemodynamics in humans.

Authors:  C A Feldstein; A O Olivieri; R P Sabarís
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Regression of left ventricular hypertrophy on long-term treatment with captopril of severe hypertensives refractory to standard triple treatment.

Authors:  U de Faire; K Lindvall; G Andersson; S Eriksson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Left ventricular hypertrophy reversal with labetalol and propranolol: a prospective randomized, double-blind study.

Authors:  J Szlachcic; W D Hall; J F Tubau; V Porter; C Vollmer; G Wollam; A Hirsch; B Massie
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 7.  Current drug treatment and treatment patterns with antihypertensive drugs.

Authors:  E D Freis; V Papademetriou
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 8.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.